For research use only. Not for therapeutic Use.
SB-265610 (Cat.No:I009325) is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). It inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.
| Catalog Number | I009325 |
| CAS Number | 211096-49-0 |
| Synonyms | SB-265610; SB 265610; SB265610.;N-(2-Bromophenyl)-N/’-(7-cyano-1H-benzotriazol-4-yl)urea |
| Molecular Formula | C14H9BrN6O |
| Purity | ≥95% |
| Target | Immunology/Inflammation |
| Solubility | Soluble in DMSO |
| Storage | Store at RT |
| IC50 | 6800 nM |
| IUPAC Name | 1-(2-bromophenyl)-3-(7-cyano-2H-benzotriazol-4-yl)urea |
| InChI | InChI=1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21) |
| InChIKey | SEDUMQWZEOMXSO-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)NC(=O)NC2=CC=C(C3=NNN=C23)C#N)Br |
| Reference | </br>1: Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Review. PubMed PMID: 26271598.</br>2:Masood A, Yi M, Belcastro R, Li J, Lopez L, Kantores C, Jankov RP, Tanswell AK. Neutrophil elastase-induced elastin degradation mediates macrophage influx and lung injury in 60% O2-exposed neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2015 Jul 1;309(1):L53-62. doi: 10.1152/ajplung.00298.2014. PubMed PMID: 26136527. |
